APATINIB: A PROMISING ORAL ANTIANGIOGENIC AGENT IN THE TREATMENT OF MULTIPLE SOLID TUMORS

Scott A. J.; Messersmith W. A.; Jimeno A.

首页> 外文期刊>Drugs of today: Medicamentos de actualidad >APATINIB: A PROMISING ORAL ANTIANGIOGENIC AGENT IN THE TREATMENT OF MULTIPLE SOLID TUMORS

【24h】

APATINIB: A PROMISING ORAL ANTIANGIOGENIC AGENT IN THE TREATMENT OF MULTIPLE SOLID TUMORS

机译：阿帕替尼：一种有望治疗多种固体肿瘤的口服抗血管生成剂

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aberrant proangiogenic pathways have long been implicated in tumorigenesis and metastasis. Antiangiogenic therapies have shown efficacy in the treatment of a variety of solid tumors including lung, breast, colon, glioblastomas, and other solid tumor types. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), is an orally bioavailable agent currently being studied in multiple tumor types. Apatinib has shown a survival benefit in gastric cancer in a phase III trial and non-small cell lung cancer in a phase II trial. With a favorable side effect profile and improved outcomes, apatinib has demonstrated a substantial potential to augment therapeutic options in a variety of tumor types.

机译：长期以来，异常的促血管生成途径与肿瘤发生和转移有关。抗血管生成疗法已显示出对多种实体瘤的治疗功效，包括肺癌，乳腺癌，结肠癌，成胶质细胞瘤和其他实体瘤类型。阿帕替尼是血管内皮生长因子受体2（VEGFR-2）的小分子抑制剂，是一种口服生物利用剂，目前正在多种肿瘤类型中进行研究。阿帕替尼已在III期临床试验中显示出对胃癌和在II期临床试验中的非小细胞肺癌具有生存获益。阿帕替尼具有良好的副作用和改善的治疗效果，已显示出在各种肿瘤类型中增加治疗选择的巨大潜力。

著录项

来源
《Drugs of today: Medicamentos de actualidad》 |2015年第4期|共7页
作者
Scott A. J.; Messersmith W. A.; Jimeno A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
Apatinib; VEGF; VEGFR-2; Antiangiogenic drugs; solid tumor;

机译：阿帕替尼;VEGF;VEGFR-2;抗血管生成药物;实体瘤;

相似文献

外文文献
中文文献
专利

1. APATINIB: A PROMISING ORAL ANTIANGIOGENIC AGENT IN THE TREATMENT OF MULTIPLE SOLID TUMORS [J] . Scott A. J., Messersmith W. A., Jimeno A. Drugs of today: Medicamentos de actualidad . 2015,第4期

机译：阿帕替尼：一种有望治疗多种固体肿瘤的口服抗血管生成剂
2. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. [J] . Dahut WL, Lakhani NJ, Gulley JL, Cancer biology & therapy . 2006,第1期

机译：在实体瘤患者中口服2-甲氧基雌二醇（一种抗血管生成和凋亡剂）的I期临床试验。
3. A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib [J] . Roy Subhajit, Narang Bawneet K., Rastogi Shiva K., Anti-cancer agents in medicinal chemistry . 2015,第1期

机译：一种新型的多重酪氨酸激酶靶向药物，探讨抗血管生成疗法治疗多种实体瘤的未来前景：卡波替尼
4. Robust LC-MS/MS Analytical Method for Quantification of β-Lapachone: A Novel Chemotherapeutic Agent for the Treatment of Solid Tumors [C] . Claudia Meek, Erling Beck, David Boothman, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2013

机译：用于定量β-leapachne的鲁棒LC-MS / MS分析方法：一种用于治疗实体瘤的新型化学治疗剂
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
6. Methylselenocysteine - a Promising Antiangiogenic Agent for Overcoming Drug Delivery Barriers in Solid Malignancies for Therapeutic Synergy with Anticancer Drugs [O] . Arup Bhattacharya -1

机译：methylselenocysteine - 一个有前途的抗血管生成剂在实体恶性肿瘤克服药物输送障碍的治疗协同作用与抗癌药物
7. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors [O] . William L. Dahut, Nehal J. Lakhani, James L. Gulley, 2006

机译：I期I-Methoxystradiol，抗血管生成和凋亡剂的临床试验，固体肿瘤患者

APATINIB: A PROMISING ORAL ANTIANGIOGENIC AGENT IN THE TREATMENT OF MULTIPLE SOLID TUMORS

摘要

著录项

相似文献

相关主题

期刊订阅